Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Classical complement pathway activation in membranoproliferative glomerulonephritis

Y M Ooi, E H Vallota, C D West

    Kidney International
    |January 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Blood amino nitrogen levels; changes in blood amino nitrogen levels following ingestion of proteins and of a protein hydrolysate in infants with normal and with deficient pancreatic function.

    American journal of diseases of children (1911)·2010
    Same author

    Nuclear emissions during self-nucleated acoustic cavitation.

    Physical review letters·2006
    Same author

    Additional evidence of nuclear emissions during acoustic cavitation.

    Physical review. E, Statistical, nonlinear, and soft matter physics·2004
    Same author

    Evidence for nuclear emissions during acoustic cavitation.

    Science (New York, N.Y.)·2002
    Same author

    Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2.

    American journal of kidney diseases : the official journal of the National Kidney Foundation·2001
    Same author

    Acute non-proliferative glomerulitis: a cause of renal failure unique to children.

    Pediatric nephrology (Berlin, Germany)·2000
    Same journal

    KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

    Kidney international·2026
    Same journal

    KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

    Kidney international·2026
    Same journal

    Crystal-Storing Histiocytosis Causing Severe AKI.

    Kidney international·2026
    Same journal

    Peritoneal dialysis in a patient with extensive burn scarring.

    Kidney international·2026
    Same journal

    COPA syndrome unmasked by anti-neutrophil cytoplasmic antibody-positive immune-complex nephritis.

    Kidney international·2026
    Same journal

    Monitoring anti-nephrin antibodies in the management of recurrent diffuse podocytopathy.

    Kidney international·2026
    See all related articles

    This study differentiates two types of membranoproliferative glomerulonephritis (MPGN) by analyzing complement pathway components. Type I MPGN shows classical pathway activation, while Type II MPGN involves the alternative pathway and C3 nephritic factor.

    Area of Science:

    • Immunology
    • Nephrology
    • Complement System Biology

    Background:

    • Membranoproliferative glomerulonephritis (MPGN) is a complex kidney disease.
    • Distinguishing between MPGN Type I and Type II is crucial for understanding disease mechanisms.
    • The complement system plays a significant role in the pathogenesis of MPGN.

    Purpose of the Study:

    • To compare complement pathway activation in Type I and Type II MPGN.
    • To investigate the role of C3 nephritic factor (C3NeF) in MPGN.
    • To elucidate the specific complement components involved in each MPGN subtype.

    Main Methods:

    • Serum samples from MPGN Type I, Type II patients, and normal subjects were analyzed.
    • Levels of classical and alternative complement pathway components were quantified.

    Related Experiment Videos

  • Activity of C3 nephritic factor (C3NeF) was measured.

    • Main Results:

    • Both MPGN types showed depressed C3 and C5 levels.
    • Type I MPGN exhibited markers of classical pathway activation (lower Clq, C4; higher correlations).
    • Type II MPGN demonstrated alternative pathway involvement (lower Factor B, higher C3NeF activity) and properdin deposition.

    Conclusions:

    • Complement system activation patterns differ significantly between MPGN Type I and Type II.
    • Type I MPGN is associated with classical pathway activation and properdin involvement.
    • Type II MPGN is characterized by alternative pathway activation, C3NeF, and distinct properdin findings.